⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20261464 | 0.76 | — | — | |
| SCHEMBL19094129 | 0.72 | — | — | |
| SCHEMBL14781645 | 0.71 | — | — | |
| SCHEMBL23851714 | 0.68 | — | — | |
| SCHEMBL23851715 | 0.68 | — | — | |
| SCHEMBL14787187 | 0.67 | — | — | |
| SCHEMBL14787163 | 0.67 | — | — | |
| SCHEMBL14787183 | 0.67 | — | — | |
| SCHEMBL14787156 | 0.67 | — | — | |
| SCHEMBL14787048 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071205-B1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-05 | — | — | EP | claimed |
| EP-2872502-B1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | claimed |
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12599582-B2 | Pyrrole compounds | ALIGOS THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4716531-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12583846-B2 | 2H-benzopyran derivatives as CRAC inhibitors | CISEN PHARMACEUTICAL CO., LTD | 2026-03-24 | — | — | US | disclosed |
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| US-20160237072-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237072-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237072-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
| EP-3055306-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | Bristol-Myers Squibb Company (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2016105485-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105485-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20150216172-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR PLANT DISEASE CONTROL | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
| WO-2015054103-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054103-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |